(Q34209231)

31 July 2017

title

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy (English)

1 reference

Adaptive radiation therapy

31 July 2017

main subject

0 references

Mitchell S Anscher

1

0 references

author name string

Lawrence B Marks

2

1 reference

31 July 2017

Timothy D Shafman

3

1 reference

31 July 2017

Robert Clough

4

1 reference

31 July 2017

Hong Huang

5

1 reference

31 July 2017

Andrea Tisch

6

1 reference

31 July 2017

Michael Munley

7

1 reference

31 July 2017

James E Herndon

8

1 reference

31 July 2017

Jennifer Garst

9

1 reference

31 July 2017

Jeffrey Crawford

10

1 reference

31 July 2017

Randy L Jirtle

11

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

International Journal of Radiation Oncology Biology Physics

31 July 2017

published in

1 reference

31 July 2017

volume

56

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

988-995

1 reference

Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Circulating IL-6 as a predictor of radiation pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Signiicant Effect of Adjuvant Chemotherapy on Survival in Locally Advanced Non-Small-Cell Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Impact of tumor control on survival in carcinoma of the lung treated with irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

The relationship between tumor response and survival following radiotherapy for carcinoma of the bronchus

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Normal tissue radiobiology: from the laboratory to the clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

The radiotherapeutic injury--a complex 'wound'.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

TGF-beta, radiation-induced pulmonary injury and lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

A new three-dimensional dose distribution reduction scheme for tubular organs

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Clinical and dosimetric predictors of radiation-induced esophageal toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

Radiation-induced hypoxia may perpetuate late normal tissue injury

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900184-6

7 January 2021

10.1016/S0360-3016(03)00184-6

Identifiers

DOI

1 reference

release_uhacz2fk3va2lgw4lv46eqmwhy

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uhacz2fk3va2lgw4lv46eqmwhy

24 November 2022

mapped directly with Wikidata item

1 reference